Erasca, Inc. Securities Fraud Lawsuit Lead Plaintiff Opportunity Announced
Rosen Law Firm is notifying purchasers of Erasca, Inc. common stock that a lead plaintiff must be appointed in a securities fraud class action lawsuit by August 10, 2026.
A law firm specializing in investor rights has announced an opportunity for investors to lead a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS).
Purchasers of Erasca common stock between January 14, 2025, and April 26, 2026, inclusive, are eligible to seek appointment as lead plaintiff. The deadline to file a lead plaintiff motion is August 10, 2026.
The lawsuit alleges that Erasca and certain executives made materially false and misleading statements. Specifically, it claims the company failed to disclose significant risks associated with its research and development activities, particularly concerning the development of a drug candidate called otiosertib. Investors allege that the company misrepresented critical safety information regarding this drug.
According to the allegations, these misrepresentations and omissions led to an artificial inflation of Erasca's stock price. The stock price subsequently declined sharply when the truth regarding the drug's safety profile was revealed. Investors who acquired Erasca stock during the specified period and suffered losses are encouraged to contact the law firm.
Rosen Law Firm is investigating the claims and is committed to representing investors in their pursuit of recoveries. The firm urges potential lead plaintiffs to act promptly to protect their rights.